title: Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer.
abstract: OBJECTIVE
  Psoriasin (S100A7) is highly expressed in preinvasive ductal carcinoma in situ of the breast and persistent expression occurs in some invasive carcinomas. This study explores the clinical significance of psoriasin in relation to patient survival in invasive breast cancer.
  
  
  METHODS
  We examined psoriasin expression by immunohistochemistry in a cohort of 122 estrogen receptor-negative invasive ductal carcinomas.
  
  
  RESULTS
  Psoriasin expression was observed in 64 of 122 cases (52%) but was not correlated with other prognostic factors (including progesterone receptor, stage, size, grade, and nodal status) within this cohort. However, in univariate analysis, psoriasin expression (nuclear and cytoplasmic) was associated with a shorter time to progression (P < 0.04) and poor survival (P < 0.03). In multivariate analysis, cytoplasmic psoriasin also emerged as independent indicator of time to progression (hazard ratio, 1.86; 95% confidence interval, 1.02-3.39; P = 0.044) and survival (hazard ratio, 2.12; 95% confidence interval, 1.06-4.23; P = 0.033).
  
  
  CONCLUSIONS
  These results suggest that psoriasin expression may be associated with a worse prognosis in estrogen receptor-negative invasive ductal carcinomas and raise the possibility that psoriasin expression may also be an indicator of risk of progression in ductal carcinoma in situ.
authors.affiliation: Departments of Pathology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, R3E OW3 Canada.
authors.forename: Ethan D
authors.initials: ED
authors.lastname: Emberley
authors.forename: Yulian
authors.initials: Y
authors.lastname: Niu
authors.forename: Catherine
authors.initials: C
authors.lastname: Njue
authors.forename: Erich V
authors.initials: EV
authors.lastname: Kliewer
authors.forename: Leigh C
authors.initials: LC
authors.lastname: Murphy
authors.forename: Peter H
authors.initials: PH
authors.lastname: Watson
mesh_terms: D000328:Adult; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D002278:Carcinoma in Situ / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism; D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002135:Calcium-Binding Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000075023:S100 Calcium Binding Protein A7; D009418:S100 Proteins; C089242:S100A7 protein, human